Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide

Treatment of Patients with Relapsed/Refractory Multiple Myeloma with Ruxolitinib, Methylprednisolone and Lenalidomide: Using Changes in Serum B-Cell Maturation Antigen (BCMA) or International Multiple Working Group (IMWG) Criteria to Determine Disease Progression in Order to Add Lenalidomide to those Failing the Ruxolitinib/Methylprednisolone Combination

Sponsor: Incyte
Protocol Number: I-RUX-20-52
Start Date: Protocol in development
Not active

(Link not available as study is not submitted to FDA. Probable submission on mid November 2023)